References
- Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitionsand outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group. Blood 2009;113:2386–93.
- Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on theinvestigation and management of primary immune thrombocytopenia. Blood 2010;115:168–86.
- Arnold DM, Kelton JG. Current options for the treatment of idiopathicthrombocytopenic purpura. Semin Hematol 2007;44:S12–S23.
- Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of theiruse in idiopathic thrombocytopenic purpura. Drugs 2008;68:901–12.
- McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associatedadverse events. Curr Opin Rheumatol 2008;20:131–7.
- Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner R, et al. Impact of chronic Immune ThrombocytopenicPurpura (ITP) on health-related quality of life: a conceptual model startingwith the patient perspective. Health Qual Life Outcomes 2008;6:13.
- Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia:increased platelet destruction and/or decreased platelet production. BrJ Hematol 2009;146:585–96.
- Newland A. Thrombopoietin receptor agonists in the treatmentof thrombocytopenia. Curr Opin Hematol 2009;16:357–64.
- Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatmentwith romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161–71.
- Kuter DJ, Bussel JB, Newland A, Wasser JS, Lyons RM, George JN, et al. Long-term efficacy and safety of romiplostimtreatment of adult patients with chronic immune thrombocytopenia (ITP): finalreport from an open-label extension study. ASH AnnualMeeting Abstracts 2010;116: Abstract68.
- Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patientswith chronic immune thrombocytopenic purpura: a double-blind randomised controlledtrial. Lancet 2008;37:395–403.
- Michel M, Desborough C. Reduced corticosteroid treatment in adultswith ITP receiving romiplostim. EHA Annual MeetingAbstracts 2009; 0226.
- Kuter DJ, Bussel JB, Newland A, de Wolf JTM, Guthrie T, Wasser J, et al. Long-term treatment with romiplostimin patients with chronic immune thrombocytopenic purpura (ITP): 3-year updatefrom an open-label extension study. ASH Annual MeetingAbstracts 2008;112:402.
- Pullarkat VA, Gernsheimer TB, Wasser JS, Newland A, Guthrie TH, de Wolf JT, et al. Quantifying the reduction in immunoglobulinuse over time in patients with chronic immune thrombocytopenic purpura receivingromiplostim (AMG 531). Am J Hematol 2009;84:538–40.